Adial Pharmaceuticals (NASDAQ:ADIL) focuses on developing treatments for addiction and disorders related to substance use. Their flagship project targets the genetic predisposition of individuals with alcohol use disorder, aiming to introduce a genetic-driven approach to treatment that could revolutionize how addictions are managed. Besides alcohol addiction, they are extending their research and development efforts to address opioid withdrawal symptoms, marking a significant stride towards tackling the opioid crisis. With a mission rooted in innovation and patient care, Adial Pharmaceuticals strives to make substantial impacts on public health by addressing some of the most challenging substance use issues facing society today.